Figure 5.

Liposomes Coated with C1-3 ScAb and Loaded with Doxorubicin Significantly Decrease Numbers of Hepatic Myofibroblasts

(A) Schematic representation of acute CCl₄ model of liver fibrosis and therapeutic treatment with C1-3/Dox liposomes. (B) Representative histological sections and graph showing average number of NIMP+ cells (neutrophils), (C) F4/80 (macrophages), and (D) PCNA in control (C1-3/empty liposomes) or C1-3/doxorubicin liposomes treated livers. (E) αSMA staining in representative control (C1-3/empty liposomes) or C1-3/doxorubicin liposome-treated animals and average αSMA positive area in both groups of livers. (F) mRNA levels of TGF-β1 as quantified by qPCR in livers of control (C1-3/empty liposomes) and C1-3/doxorubicin liposome-treated animals. Error bars in relevant panels represent mean ± SEM. *p < 0.05.